Executive Summary

Healthcare organizations — hospitals, payers, CROs and pharma — face growing demands to prove the provenance of every data element used in AI models and clinical decisions, driven by FDA expectations for explainability, payer audits, and patient-safety liability. With an estimated addressable market of roughly 30,000 organizations spending about $2.0M each per year on AI assurance and data governance (a $60.0B market), the problem is widespread and financially material. You could build a field-level data-provenance platform that captures immutable, queryable lineage metadata for individual fields across EHRs, FHIR APIs, ETL pipelines and model training sets, offering cryptographic attestations, versioning, and audit-ready reports via SaaS with on-prem connectors. Regulatory and interoperability trends—ONC/CMS rules, broader FHIR adoption, and rising FDA scrutiny—mean customers can more easily ingest and exchange provenance metadata, lowering integration friction and creating near-term demand. Rapid AI adoption in diagnosis, prior authorization and revenue-cycle workflows increases the stakes: organizations deploying dozens of models need evidence that a specific input value came from a trusted source when an adverse outcome or claim dispute arises. This approach can stand out from medium-competition incumbents (data catalogs, MDM and file-level lineage tools) by delivering true field-level granularity, pre-built FHIR-aware connectors, performant indexing for large-scale longitudinal clinical records and auditor-facing workflows that can materially shorten audit cycles from weeks to days. Strengths include clear regulatory tailwinds, a large ($60B) addressable market and measurable ROI; challenges are significant engineering complexity to scale and secure metadata for PHI, the need to change operating practices across clinical and IT teams, and persuading conservative buyers to fund the upfront instrumentation work. If you can demonstrate reliable integrations, provable cryptographic integrity, and fast audit outcomes in 2–3 pilot customers, this opportunity is worth pursuing.

Market Opportunity

Field-level data provenance for trustworthy AI in healthcare targets a $60.0B = 30,000 healthcare organizations (hospitals, payers, CROs, pharma) x $2.0M average annual lifecycle spend on AI assurance & data governance total addressable market with medium saturation and a year-over-year growth rate of 18% CAGR for healthcare AI governance and model assurance segments.

Key trends driving demand: Regulatory scrutiny -- FDA and payer expectations for explainability and audit trails increase demand for provable data lineage.; AI adoption in clinical workflows -- Rapid deployment of AI models in diagnosis, prior authorization, and revenue-cycle workflows increases need for source verification.; Interoperability mandates -- ONC/CMS rules and FHIR adoption make it easier to link provenance metadata across systems and enforce lineage.; Advances in extraction models -- LLMs and vision models reduce manual labeling, enabling automated field-level provenance at scale..

Key competitors include Collibra, Immuta, Fiddler AI, Arize AI, In-house / Manual Workarounds.

Sign in to access

Field-level data provenance for trustworthy AI in healthcare

Executive Summary

Market Validation

Market Opportunity

More in HealthTech

Replace manual pharmacy ops with AI-driven billing, inventory & CRM

Helping people manage stress & anxiety with a personalized AI companion

Cumbersome food logging -> passive AI meal capture with portion inference

HIPAA BAA blockers — AI contract review + pre-approved vendor marketplace

Reduce missed clinic appointments by automating patient outreach via WhatsApp

Too many leads not converting — automate patient conversion flow